Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Histo-blood group antigen (HBGA) status may affect vaccine efficacy due to rotavirus strains binding to HBGAs in a P genotype-dependent manner. This study aimed to determine if HBGA status affected vaccine take of the G3P[6] neonatal vaccine RV3-BB. DNA was extracted from stool samples collected in a subset (n = 164) of the RV3-BB phase IIb trial in Indonesian infants. FUT2 and FUT3 genes were amplified and sequenced, with any single-nucleotide polymorphisms analyzed to infer Lewis and secretor status. Measures of positive cumulative vaccine take were defined as serum immune response (immunoglobulin A or serum-neutralizing antibody) and/or stool excretion of RV3-BB virus. Participants were stratified by HBGA status and measures of vaccine take. In 147 of 164 participants, Lewis and secretor phenotype were determined. Positive vaccine take was recorded for 144 (97.9%) of 147 participants with the combined phenotype determined. Cumulative vaccine take was not significantly associated with secretor status (relative risk, 1.00 [95% CI, .94-1.06]; P = .97) or Lewis phenotype (relative risk, 1.03 [95% CI, .94-1.14]; P = .33), nor was a difference observed when analyzed by each component of vaccine take. The RV3-BB vaccine produced positive cumulative vaccine take, irrespective of HBGA status in Indonesian infants. © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Citation

Celeste M Donato, Amanda Handley, Sean G Byars, Nada Bogdanovic-Sakran, Eleanor A Lyons, Emma Watts, Darren S Ong, Daniel Pavlic, Jarir At Thobari, Cahya Dewi Satria, Hera Nirwati, Yati Soenarto, Julie E Bines. Vaccine Take of RV3-BB Rotavirus Vaccine Observed in Indonesian Infants Regardless of HBGA Status. The Journal of infectious diseases. 2024 Apr 12;229(4):1010-1018

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 37592804

View Full Text